Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 110

1.

Thioredoxin 1 as a serum marker for breast cancer and its use in combination with CEA or CA15-3 for improving the sensitivity of breast cancer diagnoses.

Park BJ, Cha MK, Kim IH.

BMC Res Notes. 2014 Jan 6;7:7. doi: 10.1186/1756-0500-7-7.

PMID:
24393391
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases.

Nicolini A, Tartarelli G, Carpi A, Metelli MR, Ferrari P, Anselmi L, Conte M, Berti P, Miccoli P.

BMC Cancer. 2006 Nov 20;6:269.

PMID:
17116247
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

HER-2 gene amplification, serum nucleosomes, CEA and CA15.3 tumor markers in breast cancer patients.

Zeiwar MM, Zaki SM, Mohammad LA, Zidan AA, El Nagar MR.

Egypt J Immunol. 2007;14(2):29-41.

PMID:
20306655
[PubMed - indexed for MEDLINE]
4.

Plasma mammaglobin messenger RNA in breast cancer patients as an addition to serum tumor.

El-Attar NI, Gaefar HA.

Egypt J Immunol. 2007;14(2):111-21.

PMID:
20306663
[PubMed - indexed for MEDLINE]
5.

Comparison of serum CA15-3 and CEA in breast cancer.

Hou MF, Huang TJ, Hsieh JS, Huang YS, Huang CJ, Chan HM, Wang JY, Chen YL, Jong SB, Yang CC.

Gaoxiong Yi Xue Ke Xue Za Zhi. 1995 Dec;11(12):660-6.

PMID:
8551526
[PubMed - indexed for MEDLINE]
6.

Activated leukocyte cell adhesion molecule: a novel biomarker for breast cancer.

Kulasingam V, Zheng Y, Soosaipillai A, Leon AE, Gion M, Diamandis EP.

Int J Cancer. 2009 Jul 1;125(1):9-14. doi: 10.1002/ijc.24292.

PMID:
19322904
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Use of CA15-3, CEA and prolactin for the primary diagnosis of breast cancer and correlation with the prognostic factors at the time of initial diagnosis.

Arslan N, Serdar M, Deveci S, Ozturk B, Narin Y, Ilgan S, Ozturk E, Ozguven MA.

Ann Nucl Med. 2000 Oct;14(5):395-9.

PMID:
11108173
[PubMed - indexed for MEDLINE]
8.

Combined measurement of serum sialyl Lewis X with serum CA15-3 in breast cancer patients.

Kurebayashi J, Nomura T, Hirono M, Okubo S, Udagawa K, Shiiki S, Ikeda M, Nakashima K, Tanaka K, Sonoo H.

Jpn J Clin Oncol. 2006 Mar;36(3):150-3. Epub 2006 Mar 6.

PMID:
16520359
[PubMed - indexed for MEDLINE]
Free Article
9.

Evaluation of serum CA15-3 determination with CEA and TPA in the post-operative follow-up of breast cancer patients.

Nicolini A, Colombini C, Luciani L, Carpi A, Giuliani L.

Br J Cancer. 1991 Jul;64(1):154-8.

PMID:
1854615
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Serial tumour markers serum carcinoembryonic antigen and cancer antigen 15-3 assays in detecting symptomatic metastasis in breast cancer patients.

Bahrami A, Mortazavizadeh MR, Yazdi MF, Chamani M.

East Mediterr Health J. 2012 Oct;18(10):1055-9.

PMID:
23301361
[PubMed - indexed for MEDLINE]
11.

[Preoperative serum CA15.3 and CEA levels and clinical-biological parameters in breast tumors].

Ruibal A, Garrido Pumar M, Arias JI.

Rev Esp Med Nucl. 2006 May-Jun;25(3):180-3. Spanish.

PMID:
16762272
[PubMed - indexed for MEDLINE]
12.

N(1),N(12)-Diacetylspermine as a sensitive and specific novel marker for early- and late-stage colorectal and breast cancers.

Hiramatsu K, Takahashi K, Yamaguchi T, Matsumoto H, Miyamoto H, Tanaka S, Tanaka C, Tamamori Y, Imajo M, Kawaguchi M, Toi M, Mori T, Kawakita M.

Clin Cancer Res. 2005 Apr 15;11(8):2986-90.

PMID:
15837752
[PubMed - indexed for MEDLINE]
Free Article
13.

Prognostic significance of serum Her2/neu, BCL2, CA15-3 and CEA in breast cancer patients: a short follow-up.

Samy N, Ragab HM, El Maksoud NA, Shaalan M.

Cancer Biomark. 2010;6(2):63-72. doi: 10.3233/CBM-2009-0119.

PMID:
20571232
[PubMed - indexed for MEDLINE]
14.

Evaluation of serum CA27.29, CA15-3 and CEA in patients with breast cancer.

Hou MF, Chen YL, Tseng TF, Lin CM, Chen MS, Huang CJ, Huang YS, Hsieh JS, Huang TJ, Jong SB, Huang YF.

Kaohsiung J Med Sci. 1999 Sep;15(9):520-8.

PMID:
10561976
[PubMed - indexed for MEDLINE]
15.

Is parathyroid hormone-related protein a sensitive serum marker in advanced breast cancer?

Pyke CM, Menezes G, Purdie DM, Johnson S, Cowley D.

Aust N Z J Surg. 1997 May;67(5):256-9.

PMID:
9152154
[PubMed - indexed for MEDLINE]
16.

Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA).

Giovanella L, Ceriani L, Giardina G, Bardelli D, Tanzi F, Garancini S.

Clin Chem Lab Med. 2002 Mar;40(3):298-303.

PMID:
12005221
[PubMed - indexed for MEDLINE]
17.

Serum microRNA-155 as a potential biomarker to track disease in breast cancer.

Sun Y, Wang M, Lin G, Sun S, Li X, Qi J, Li J.

PLoS One. 2012;7(10):e47003. doi: 10.1371/journal.pone.0047003. Epub 2012 Oct 10.

PMID:
23071695
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

The usefulness of CA15.3, mucin-like carcinoma-associated antigen and carcinoembryonic antigen in determining the clinical course in patients with metastatic breast cancer.

Deprés-Brummer P, Itzhaki M, Bakker PJ, Hoek FJ, Veenhof KH, de Wit R.

J Cancer Res Clin Oncol. 1995;121(7):419-22.

PMID:
7635872
[PubMed - indexed for MEDLINE]
19.

CA27.29: a valuable marker for breast cancer management. A confirmatory multicentric study on 603 cases.

Gion M, Mione R, Leon AE, Lüftner D, Molina R, Possinger K, Robertson JF.

Eur J Cancer. 2001 Feb;37(3):355-63.

PMID:
11239757
[PubMed - indexed for MEDLINE]
20.

Detection of aberrant promoter methylation of GSTP1, RASSF1A, and RARβ2 in serum DNA of patients with breast cancer by a newly established one-step methylation-specific PCR assay.

Yamamoto N, Nakayama T, Kajita M, Miyake T, Iwamoto T, Kim SJ, Sakai A, Ishihara H, Tamaki Y, Noguchi S.

Breast Cancer Res Treat. 2012 Feb;132(1):165-73. doi: 10.1007/s10549-011-1575-2. Epub 2011 May 19.

PMID:
21594664
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk